These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14525545)

  • 1. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
    Clements M; Law M; Pedersen C; Kaldor J;
    HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.
    Lodi S; Phillips A; Touloumi G; Geskus R; Meyer L; Thiébaut R; Pantazis N; Amo JD; Johnson AM; Babiker A; Porter K;
    Clin Infect Dis; 2011 Oct; 53(8):817-25. PubMed ID: 21921225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
    ; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
    Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
    Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
    Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.
    CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration
    HIV Med; 2000 Oct; 1(4):224-31. PubMed ID: 11737353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
    Wolbers M; Babiker A; Sabin C; Young J; Dorrucci M; Chêne G; Mussini C; Porter K; Bucher HC;
    PLoS Med; 2010 Feb; 7(2):e1000239. PubMed ID: 20186270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.
    Dorrucci M; Rezza G; Porter K; Phillips A;
    J Infect Dis; 2007 Feb; 195(4):525-34. PubMed ID: 17230412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of tuberculosis following HIV seroconversion in high-income countries.
    Lodi S; del Amo J; d'Arminio Monforte A; Abgrall S; Sabin C; Morrison C; Furrer H; Muga R; Porter K; Girardi E;
    Thorax; 2013 Mar; 68(3):207-13. PubMed ID: 23117980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
    Phillips A; Pezzotti P;
    AIDS; 2004 Jan; 18(1):51-8. PubMed ID: 15090829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion.
    Thiébaut R; Jacqmin-Gadda H; Walker S; Sabin C; Prins M; Del Amo J; Porter K; Dabis F; Chêne G;
    HIV Med; 2006 Jan; 7(1):1-9. PubMed ID: 16313286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
    Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):158-65. PubMed ID: 11588510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
    May MT; Hogg RS; Justice AC; Shepherd BE; Costagliola D; Ledergerber B; Thiébaut R; Gill MJ; Kirk O; van Sighem A; Saag MS; Navarro G; Sobrino-Vegas P; Lampe F; Ingle S; Guest JL; Crane HM; D'Arminio Monforte A; Vehreschild JJ; Sterne JA;
    Int J Epidemiol; 2012 Dec; 41(6):1807-20. PubMed ID: 23148105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.